Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 68
Filter
1.
PLoS Genet ; 18(6): e1010260, 2022 06.
Article in English | MEDLINE | ID: mdl-35727838

ABSTRACT

The shelterin protein POT1 has been found mutated in many different familial and sporadic cancers, however, no mouse models to understand the pathobiology of these mutations have been developed so far. To address the molecular mechanisms underlying the tumorigenic effects of POT1 mutant proteins in humans, we have generated a mouse model for the human POT1R117C mutation found in Li-Fraumeni-Like families with cases of cardiac angiosarcoma by introducing this mutation in the Pot1a endogenous locus, knock-in for Pot1aR117C. We find here that both mouse embryonic fibroblasts (MEFs) and tissues from Pot1a+/ki mice show longer telomeres than wild-type controls. Longer telomeres in Pot1a+/ki MEFs are dependent on telomerase activity as they are not found in double mutant Pot1a+/ki Tert-/- telomerase-deficient MEFs. By using complementation assays we further show that POT1a pR117C exerts dominant-negative effects at telomeres. As in human Li-Fraumeni patients, heterozygous Pot1a+/ki mice spontaneously develop a high incidence of angiosarcomas, including cardiac angiosarcomas, and this is associated to the presence of abnormally long telomeres in endothelial cells as well as in the tumors. The Pot1a+/R117C mouse model constitutes a useful tool to understand human cancers initiated by POT1 mutations.


Subject(s)
Hemangiosarcoma , Shelterin Complex/metabolism , Telomerase , Telomere-Binding Proteins/metabolism , Animals , Endothelial Cells/metabolism , Fibroblasts/metabolism , Hemangiosarcoma/genetics , Humans , Li-Fraumeni Syndrome , Mice , Mutation , Telomerase/genetics , Telomerase/metabolism , Telomere/genetics , Telomere/metabolism , Telomere-Binding Proteins/genetics
2.
Cell ; 135(4): 609-22, 2008 Nov 14.
Article in English | MEDLINE | ID: mdl-19013273

ABSTRACT

Telomerase confers limitless proliferative potential to most human cells through its ability to elongate telomeres, the natural ends of chromosomes, which otherwise would undergo progressive attrition and eventually compromise cell viability. However, the role of telomerase in organismal aging has remained unaddressed, in part because of the cancer-promoting activity of telomerase. To circumvent this problem, we have constitutively expressed telomerase reverse transcriptase (TERT), one of the components of telomerase, in mice engineered to be cancer resistant by means of enhanced expression of the tumor suppressors p53, p16, and p19ARF. In this context, TERT overexpression improves the fitness of epithelial barriers, particularly the skin and the intestine, and produces a systemic delay in aging accompanied by extension of the median life span. These results demonstrate that constitutive expression of Tert provides antiaging activity in the context of a mammalian organism.


Subject(s)
Aging , Gene Expression Regulation, Enzymologic , Gene Expression Regulation, Neoplastic , Neoplasms/genetics , Neoplasms/metabolism , Telomerase/metabolism , Animals , Cell Survival , Epidermis/metabolism , Humans , Insulin-Like Growth Factor I/biosynthesis , Keratinocytes/cytology , Mice , Mice, Transgenic , Models, Biological , Stem Cells/cytology
3.
Hepatology ; 70(2): 650-665, 2019 08.
Article in English | MEDLINE | ID: mdl-30155948

ABSTRACT

Liver ischemia and reperfusion injury (IRI) remains a serious clinical problem affecting liver transplantation outcomes. IRI causes up to 10% of early organ failure and predisposes to chronic rejection. Cyclooxygenase-2 (COX-2) is involved in different liver diseases, but the significance of COX-2 in IRI is a matter of controversy. This study was designed to elucidate the role of COX-2 induction in hepatocytes against liver IRI. In the present work, hepatocyte-specific COX-2 transgenic mice (hCOX-2-Tg) and their wild-type (Wt) littermates were subjected to IRI. hCOX-2-Tg mice exhibited lower grades of necrosis and inflammation than Wt mice, in part by reduced hepatic recruitment and infiltration of neutrophils, with a concomitant decrease in serum levels of proinflammatory cytokines. Moreover, hCOX-2-Tg mice showed a significant attenuation of the IRI-induced increase in oxidative stress and hepatic apoptosis, an increase in autophagic flux, and a decrease in endoplasmic reticulum stress compared to Wt mice. Interestingly, ischemic preconditioning of Wt mice resembles the beneficial effects observed in hCOX-2-Tg mice against IRI due to a preconditioning-derived increase in endogenous COX-2, which is mainly localized in hepatocytes. Furthermore, measurement of prostaglandin E2 (PGE2 ) levels in plasma from patients who underwent liver transplantation revealed a significantly positive correlation of PGE2 levels and graft function and an inverse correlation with the time of ischemia. Conclusion: These data support the view of a protective effect of hepatic COX-2 induction and the consequent rise of derived prostaglandins against IRI.


Subject(s)
Cyclooxygenase 2/biosynthesis , Hepatocytes/enzymology , Liver/blood supply , Reperfusion Injury/etiology , Animals , Cyclooxygenase 2/physiology , Male , Mice , Mice, Transgenic
4.
Genes Dev ; 23(17): 2060-75, 2009 Sep 01.
Article in English | MEDLINE | ID: mdl-19679647

ABSTRACT

The telomere repeat-binding factor 1 (TERF1, referred to hereafter as TRF1) is a component of mammalian telomeres whose role in telomere biology and disease has remained elusive. Here, we report on cells and mice conditionally deleted for TRF1. TRF1-deleted mouse embryonic fibroblasts (MEFs) show rapid induction of senescence, which is concomitant with abundant telomeric gamma-H2AX foci and activation of the ATM/ATR downstream checkpoint kinases CHK1 and CHK2. DNA damage foci are rescued by both ATM and ATM/ATR inhibitors, further indicating that both signaling pathways are activated upon TRF1 deletion. Abrogation of the p53 and RB pathways bypasses senescence but leads to chromosomal instability including sister chromatid fusions, chromosome concatenation, and occurrence of multitelomeric signals (MTS). MTS are also elevated in ATR-deficient MEFs or upon treatment with aphidicolin, two conditions known to induce breakage at fragile sites, suggesting that TRF1-depleted telomeres are prone to breakage. To address the impact of these molecular defects in the organism, we deleted TRF1 in stratified epithelia of TRF1(Delta/Delta)K5-Cre mice. These mice die perinatally and show skin hyperpigmentation and epithelial dysplasia, which are associated with induction of telomere-instigated DNA damage, activation of the p53/p21 and p16 pathways, and cell cycle arrest in vivo. p53 deficiency rescues mouse survival but leads to development of squamous cell carcinomas, demonstrating that TRF1 suppresses tumorigenesis. Together, these results demonstrate that dysfunction of a telomere-binding protein is sufficient to produce severe telomeric damage in the absence of telomere shortening, resulting in premature tissue degeneration and development of neoplastic lesions.


Subject(s)
Chromosome Fragility , Protein Deficiency/complications , Skin Diseases/etiology , Skin Neoplasms/etiology , Telomere/genetics , Telomeric Repeat Binding Protein 1/deficiency , Telomeric Repeat Binding Protein 1/metabolism , Aging/metabolism , Animals , Cell Cycle/physiology , Cell Line , Cyclin-Dependent Kinase Inhibitor p21/metabolism , DNA Damage/genetics , E2F1 Transcription Factor/metabolism , Epidermal Cells , Epidermis/pathology , Fibroblasts/cytology , Fibroblasts/metabolism , Gene Expression Regulation , Hyperpigmentation/etiology , Hyperpigmentation/genetics , Mice , Mice, Knockout , Mutation/genetics , Neoplasm Proteins/metabolism , Neoplasms/genetics , Skin Diseases/genetics , Skin Neoplasms/genetics , Stem Cells/pathology , Telomeric Repeat Binding Protein 1/genetics , Tumor Suppressor Protein p53/metabolism
5.
Nat Genet ; 37(10): 1063-71, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16142233

ABSTRACT

TRF2 is a telomere-binding protein that has a role in telomere protection. We generated mice that overexpress TRF2 in the skin. These mice had a severe phenotype in the skin in response to light, consisting of premature skin deterioration, hyperpigmentation and increased skin cancer, which resembles the human syndrome xeroderma pigmentosum. Keratinocytes from these mice were hypersensitive to ultraviolet irradiation and DNA crosslinking agents. The skin cells of these mice had marked telomere shortening, loss of the telomeric G-strand overhang and increased chromosomal instability. Telomere loss in these mice was mediated by XPF, a structure-specific nuclease involved in ultraviolet-induced damage repair and mutated in individuals with xeroderma pigmentosum. These findings suggest that TRF2 provides a crucial link between telomere function and ultraviolet-induced damage repair, whose alteration underlies genomic instability, cancer and aging. Finally, we show that a number of human skin tumors have increased expression of TRF2, further highlighting a role for TRF2 in skin cancer.


Subject(s)
Aging, Premature/genetics , DNA-Binding Proteins/metabolism , Skin Neoplasms/genetics , Telomere/genetics , Telomeric Repeat Binding Protein 2/genetics , Animals , Cattle , Cross-Linking Reagents , DNA Damage/genetics , Disease Models, Animal , Humans , Keratinocytes/drug effects , Keratinocytes/radiation effects , Mice , Mice, Mutant Strains , RNA, Messenger/analysis , RNA, Messenger/metabolism , RNA, Neoplasm/chemistry , Sequence Deletion , Skin Neoplasms/chemistry , Skin Neoplasms/metabolism , Telomere/metabolism , Telomeric Repeat Binding Protein 2/metabolism , Transcriptional Activation , Ultraviolet Rays
6.
Nature ; 448(7151): 375-9, 2007 Jul 19.
Article in English | MEDLINE | ID: mdl-17637672

ABSTRACT

The tumour-suppressor pathway formed by the alternative reading frame protein of the Cdkn2a locus (Arf) and by p53 (also called Trp53) plays a central part in the detection and elimination of cellular damage, and this constitutes the basis of its potent cancer protection activity. Similar to cancer, ageing also results from the accumulation of damage and, therefore, we have reasoned that Arf/p53 could have anti-ageing activity by alleviating the load of age-associated damage. Here we show that genetically manipulated mice with increased, but otherwise normally regulated, levels of Arf and p53 present strong cancer resistance and have decreased levels of ageing-associated damage. These observations extend the protective role of Arf/p53 to ageing, revealing a previously unknown anti-ageing mechanism and providing a rationale for the co-evolution of cancer resistance and longevity.


Subject(s)
Aging/physiology , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Longevity/physiology , Oxidative Stress , Tumor Suppressor Protein p53/metabolism , Aging/genetics , Aging/pathology , Animals , Antioxidants/metabolism , Cells, Cultured , Cyclin-Dependent Kinase Inhibitor p16/genetics , Disease Susceptibility , Fibroblasts , Longevity/genetics , Mice , Neoplasms/genetics , Neoplasms/pathology , Oxidative Stress/genetics , Time Factors , Tumor Suppressor Protein p53/genetics
7.
Dev Cell ; 13(6): 872-83, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18061568

ABSTRACT

Achondroplasias are the most common genetic forms of dwarfism in humans. They are associated with activating mutations in FGFR3, which signal through the Stat and MAPK pathways in a ligand-independent manner to impair chondrocyte proliferation and differentiation. Snail1 has been implicated in chondrocyte differentiation as it represses Collagen II and aggrecan transcription in vitro. Here we demonstrate that Snail1 overexpression in the developing bone leads to achondroplasia in mice. Snail1 acts downstream of FGFR3 signaling in chondrocytes, regulating both Stat and MAPK pathways. Moreover, FGFR3 requires Snail1 during bone development and disease as the inhibition of Snail1 abolishes its signaling even through achondroplastic- and thanatophoric-activating FGFR3 forms. Significantly, Snail1 is aberrantly upregulated in thanatophoric versus normal cartilages from stillborns. Thus, Snail activity may likely be considered a target for achondroplasia therapies.


Subject(s)
Achondroplasia/metabolism , Chondrocytes/metabolism , Chondrogenesis/physiology , Receptor, Fibroblast Growth Factor, Type 3/metabolism , Signal Transduction , Transcription Factors/physiology , Animals , Blotting, Western , Cartilage/metabolism , Cell Proliferation , Hindlimb/embryology , Hindlimb/metabolism , Humans , Mice/embryology , Mice, Transgenic , Receptor, Fibroblast Growth Factor, Type 3/genetics , Reverse Transcriptase Polymerase Chain Reaction , Snail Family Transcription Factors , Tamoxifen/pharmacology , Transcription, Genetic
8.
Nat Med ; 11(9): 933-5, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16127435

ABSTRACT

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease generated by deregulation of T cell-mediated B-cell activation, which results in glomerulonephritis and renal failure. Disease is treated with immunosuppressants and cytostatic agents that have numerous side effects. Here we examine the use of inhibitors of phosphoinositide 3-kinase (PI3K) gamma, a lipid kinase that regulates inflammation, in the MRL-lpr mouse model of SLE. Treatment reduced glomerulonephritis and prolonged lifespan, suggesting that P13Kgamma may be a useful target in the treatment of chronic inflammation.


Subject(s)
Enzyme Inhibitors/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Lupus Nephritis/prevention & control , Phosphoinositide-3 Kinase Inhibitors , Quinoxalines/pharmacology , Thiazolidinediones/pharmacology , Animals , Disease Models, Animal , Female , Male , Mice , Mice, Mutant Strains
9.
Proc Natl Acad Sci U S A ; 106(46): 19393-8, 2009 Nov 17.
Article in English | MEDLINE | ID: mdl-19887628

ABSTRACT

Telomeres are heterochromatic structures at chromosome ends essential for chromosomal stability. Telomere shortening and the accumulation of dysfunctional telomeres are associated with organismal aging. Using telomerase-deficient TRF2-overexpressing mice (K5TRF2/Terc(-/-)) as a model for accelerated aging, we show that telomere shortening is paralleled by a gradual deregulation of the mammalian transcriptome leading to cumulative changes in a defined set of genes, including up-regulation of the mTOR and Akt survival pathways and down-regulation of cell cycle and DNA repair pathways. Increased DNA damage from dysfunctional telomeres leads to reduced deposition of H3K27me3 onto the inactive X chromosome (Xi), impaired association of the Xi with telomeric transcript accumulations (Tacs), and reactivation of an X chromosome-linked K5TRF2 transgene that is subjected to X-chromosome inactivation in female mice with sufficiently long telomeres. Exogenously induced DNA damage also disrupts Xi-Tacs, suggesting DNA damage at the origin of these alterations. Collectively, these findings suggest that critically short telomeres activate a persistent DNA damage response that alters gene expression programs in a nonstochastic manner toward cell cycle arrest and activation of survival pathways, as well as impacts the maintenance of epigenetic memory and nuclear organization, thereby contributing to organismal aging.


Subject(s)
Aging, Premature/genetics , DNA Damage/genetics , Skin/metabolism , Telomere/metabolism , X Chromosome Inactivation , Aging, Premature/metabolism , Aging, Premature/pathology , Animals , Cell Cycle/genetics , Female , Gene Expression Profiling , Keratin-15 , Keratin-5/genetics , Male , Mice , Mice, Transgenic , Skin/pathology , Telomerase/genetics , Telomerase/metabolism , Telomeric Repeat Binding Protein 2/genetics , Telomeric Repeat Binding Protein 2/metabolism , Transcription, Genetic
10.
J Clin Invest ; 132(7)2022 04 01.
Article in English | MEDLINE | ID: mdl-35192545

ABSTRACT

The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression.


Subject(s)
Breast Neoplasms , Tumor Microenvironment , Animals , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Female , Fibroblasts/metabolism , Humans , Mice , Oncostatin M/genetics , Oncostatin M/metabolism , Signal Transduction
11.
Lab Invest ; 91(11): 1634-42, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21876534

ABSTRACT

The cell cycle inhibitors p21(Waf1/Cip1) and p27(Kip1) are frequently downregulated in many human cancers, and correlate with a worse prognosis. We show here that combined deficiency in p21 and p27 proteins in mice is linked to more aggressive spontaneous tumorigenesis, resulting in a decreased lifespan. The most common tumors developed in p21p27 double-null mice were endocrine, with a higher incidence of pituitary adenomas, pheochromocytomas and thyroid adenomas. The combined absence of p21 and p27 proteins delays the incidence of radiation-induced thymic lymphomas with a higher apoptotic rate, measured by active caspase-3 and cleaved PARP-1 immunoexpresion. These results provide experimental evidence for a cooperation of both cyclin-dependent kinase inhibitors in tumorigenesis in mice.


Subject(s)
Cell Transformation, Neoplastic/genetics , Cyclin-Dependent Kinase Inhibitor p21/deficiency , Cyclin-Dependent Kinase Inhibitor p27/deficiency , Animals , Caspase 3/metabolism , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p27/genetics , DNA Primers/genetics , Endocrine Gland Neoplasms/genetics , Genotype , Immunohistochemistry , Kaplan-Meier Estimate , Mice , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/metabolism , Polymerase Chain Reaction
12.
Gastroenterology ; 138(4): 1374-83, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20004201

ABSTRACT

BACKGROUND & AIMS: A large body of evidence supports a correlation between inflammation and cancer, although the molecular mechanisms that govern this process are incompletely understood. Phosphatidylinositol 3-kinase (PI3K) is an enzyme that regulates the immune response and contributes to cell transformation in several tumor types. Here, we address the role of the PI3Kgamma isoform in inflammatory bowel disease and in the development of colitis-associated cancer. METHODS: PI3Kgamma(-/-) and control mice were repeatedly treated with dextran sulfate sodium to induce chronic colitis and colitis-associated cancer. Colorectal tumor burden and colon inflammation were evaluated in these mice. Leukocyte populations in colon were characterized by flow cytometry analysis. RESULTS: PI3Kgamma-deficient mice had a lower incidence of colitis-associated tumors, as well as reduced tumor multiplicity and smaller tumor size compared with controls. Reduced tumor development paralleled less colon inflammation in PI3Kgamma-deficient mice. Analysis of leukocyte populations in the colon of PI3Kgamma-deficient mice showed defective activation and infiltration of myeloid cells and defective recruitment of T cells to the colon compared with controls. CONCLUSIONS: PI3Kgamma regulates the innate immune response in a murine model of ulcerative colitis, thereby controlling colon inflammation and tumor formation.


Subject(s)
Colitis/etiology , Colorectal Neoplasms/etiology , Phosphatidylinositol 3-Kinases/physiology , Animals , Azoxymethane , CD4-Positive T-Lymphocytes/physiology , Colitis/immunology , Colitis/prevention & control , Colon/immunology , Colorectal Neoplasms/prevention & control , Dextran Sulfate , Disease Models, Animal , Immunity, Innate , Inflammatory Bowel Diseases/etiology , Inflammatory Bowel Diseases/immunology , Mice , Phosphoinositide-3 Kinase Inhibitors
13.
Nature ; 436(7051): 642, 2005 Aug 04.
Article in English | MEDLINE | ID: mdl-16079833

ABSTRACT

Oncogene-induced senescence is a cellular response that may be crucial for protection against cancer development, but its investigation has so far been restricted to cultured cells that have been manipulated to overexpress an oncogene. Here we analyse tumours initiated by an endogenous oncogene, ras, and show that senescent cells exist in premalignant tumours but not in malignant ones. Senescence is therefore a defining feature of premalignant tumours that could prove valuable in the diagnosis and prognosis of cancer.


Subject(s)
Cellular Senescence , Lung Neoplasms/pathology , Precancerous Conditions/pathology , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Alleles , Animals , Biomarkers, Tumor/analysis , Biomarkers, Tumor/metabolism , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Cell Transformation, Neoplastic/pathology , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Disease Models, Animal , Disease Progression , Gene Expression Regulation, Neoplastic , Genes, ras/genetics , Heterochromatin/genetics , Heterochromatin/metabolism , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , Mice , Mice, Transgenic , Oligonucleotide Array Sequence Analysis , Precancerous Conditions/genetics , Precancerous Conditions/metabolism , beta-Galactosidase/genetics , beta-Galactosidase/metabolism
14.
Mol Cancer ; 9: 196, 2010 Jul 22.
Article in English | MEDLINE | ID: mdl-20649976

ABSTRACT

BACKGROUND: ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most of them eventually relapse. The existence of this population of particularly aggressive and non-responding or relapsing patients urges the search for novel therapies. The purpose of this study was to determine whether cannabinoids might constitute a new therapeutic tool for the treatment of ErbB2-positive breast tumors. We analyzed their antitumor potential in a well established and clinically relevant model of ErbB2-driven metastatic breast cancer: the MMTV-neu mouse. We also analyzed the expression of cannabinoid targets in a series of 87 human breast tumors. RESULTS: Our results show that both Delta9-tetrahydrocannabinol, the most abundant and potent cannabinoid in marijuana, and JWH-133, a non-psychotropic CB2 receptor-selective agonist, reduce tumor growth, tumor number, and the amount/severity of lung metastases in MMTV-neu mice. Histological analyses of the tumors revealed that cannabinoids inhibit cancer cell proliferation, induce cancer cell apoptosis, and impair tumor angiogenesis. Cannabinoid antitumoral action relies, at least partially, on the inhibition of the pro-tumorigenic Akt pathway. We also found that 91% of ErbB2-positive tumors express the non-psychotropic cannabinoid receptor CB2. CONCLUSIONS: Taken together, these results provide a strong preclinical evidence for the use of cannabinoid-based therapies for the management of ErbB2-positive breast cancer.


Subject(s)
Breast Neoplasms/pathology , Cannabinoids/pharmacology , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Receptor, ErbB-2/physiology , Breast Neoplasms/metabolism , Disease Progression , Down-Regulation , Female , Humans , Neoplasm Metastasis , Receptor, Cannabinoid, CB2/metabolism
15.
Sci Rep ; 10(1): 357, 2020 01 15.
Article in English | MEDLINE | ID: mdl-31941916

ABSTRACT

The developmental regulator SOX9 is linked to cancer progression mainly as a result of its role in the regulation of cancer stem cells (CSCs). However, its activity in the differentiated cells that constitute the heterogeneous tumor bulk has not been extensively studied. In this work, we addressed this aspect in gastric cancer, glioblastoma and pancreatic adenocarcinoma. SOX9 silencing studies revealed that SOX9 is required for cancer cell survival, proliferation and evasion of senescence in vitro and tumor growth in vivo. Gain of-SOX9 function showed that high levels of SOX9 promote tumor cell proliferation in vitro and in vivo. Mechanistically, the modulation of SOX9 changed the expression of the transcriptional repressor BMI1 in the same direction in the three types of cancer, and the expression of the tumor suppressor p21CIP in the opposite direction. In agreement with this, SOX9 expression positively correlated with BMI1 levels and inversely with p21CIP in clinical samples of the different cancers. Moreover, BMI1 re-establishment in SOX9-silenced tumor cells restored cell viability and proliferation as well as decreased p21CIP in vitro and tumor growth in vivo. These results indicate that BMI1 is a critical effector of the pro-tumoral activity of SOX9 in tumor bulk cells through the repression of p21CIP. Our results highlight the relevance of the SOX9-BMI1-p21CIP axis in tumor progression, shedding novel opportunities for therapeutic development.


Subject(s)
Cyclin-Dependent Kinase Inhibitor p21/metabolism , Neoplasms/genetics , Polycomb Repressive Complex 1/metabolism , SOX9 Transcription Factor/metabolism , Adenocarcinoma , Cell Line, Tumor , Cell Proliferation , Cell Survival , Disease Progression , Gene Expression Regulation, Neoplastic , Glioblastoma , Humans , Neoplasms/metabolism , Neoplastic Processes , Pancreatic Neoplasms , SOX9 Transcription Factor/genetics , Stomach Neoplasms
16.
Cancers (Basel) ; 12(9)2020 Sep 11.
Article in English | MEDLINE | ID: mdl-32932846

ABSTRACT

Prostate cancer is the most frequent malignancy in European men and the second worldwide. One of the major oncogenic events in this disease includes amplification of the transcription factor cMYC. Amplification of this oncogene in chromosome 8q24 occurs concomitantly with the copy number increase in a subset of neighboring genes and regulatory elements, but their contribution to disease pathogenesis is poorly understood. Here we show that TRIB1 is among the most robustly upregulated coding genes within the 8q24 amplicon in prostate cancer. Moreover, we demonstrate that TRIB1 amplification and overexpression are frequent in this tumor type. Importantly, we find that, parallel to its amplification, TRIB1 transcription is controlled by cMYC. Mouse modeling and functional analysis revealed that aberrant TRIB1 expression is causal to prostate cancer pathogenesis. In sum, we provide unprecedented evidence for the regulation and function of TRIB1 in prostate cancer.

17.
J Exp Med ; 217(6)2020 06 01.
Article in English | MEDLINE | ID: mdl-32219437

ABSTRACT

Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.


Subject(s)
Prostatic Neoplasms/enzymology , Protein Serine-Threonine Kinases/genetics , AMP-Activated Protein Kinase Kinases , AMP-Activated Protein Kinases , Animals , Cell Line, Tumor , Disease Progression , Epithelium/enzymology , Epithelium/pathology , HEK293 Cells , Heterozygote , Humans , Male , Mice, Inbred C57BL , Mice, Nude , Mutant Proteins/metabolism , Neoplasm Metastasis , PTEN Phosphohydrolase/metabolism , Prostate/enzymology , Prostate/pathology , Protein Serine-Threonine Kinases/deficiency , Protein Serine-Threonine Kinases/metabolism
18.
Dev Cell ; 6(2): 303-9, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14960283

ABSTRACT

The atypical PKCs (aPKCs) have been implicated genetically in at least two independent signaling cascades that control NF-kappa B and cell polarity, through the interaction with the adapters p62 and Par-6, respectively. P62 binds TRAF6, which plays an essential role in osteoclastogenesis and bone remodeling. Recently, p62 mutations have been shown to be the cause of the 5q35-linked Paget's disease of bone, a genetic disorder characterized by aberrant osteoclastic activity. Here we show that p62, like TRAF6, is upregulated during RANK-L-induced osteoclastogenesis and that the genetic inactivation of p62 in mice leads to impaired osteoclastogenesis in vitro and in vivo, as well as inhibition of IKK activation and NF-kappa B nuclear translocation. In addition, RANK-L stimulation leads to the inducible formation of a ternary complex involving TRAF6, p62, and the aPKCs. These observations demonstrate that p62 is an important mediator during osteoclastogenesis and induced bone remodeling.


Subject(s)
Bone Remodeling/physiology , Carrier Proteins/metabolism , Glycoproteins/physiology , Immediate-Early Proteins/metabolism , Osteogenesis/physiology , Protein Kinase C/metabolism , Receptors, Cytoplasmic and Nuclear/physiology , Transcription Factors , Animals , Blotting, Southern , Bone Marrow , Bone Resorption , Carrier Proteins/genetics , Cell Count , Cells, Cultured , Electrophoretic Mobility Shift Assay , Embryo, Mammalian , Enzyme-Linked Immunosorbent Assay , Fibroblasts/drug effects , Fibroblasts/metabolism , Gene Expression/physiology , Glycoproteins/genetics , Hematoxylin/metabolism , I-kappa B Kinase , Immediate-Early Proteins/genetics , Immunoblotting , Interleukin-6/blood , Macrophage Colony-Stimulating Factor/pharmacology , Macrophages/metabolism , Mice , Mice, Knockout , NF-kappa B/metabolism , Osteoclasts/metabolism , Osteoprotegerin , Parathyroid Hormone-Related Protein/metabolism , Precipitin Tests , Protein Kinase C/genetics , Protein Kinase C-epsilon , Protein Serine-Threonine Kinases/metabolism , Proteins/metabolism , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Tumor Necrosis Factor , TNF Receptor-Associated Factor 6 , Time Factors , Transcription Factor TFIIH
19.
J Cell Biol ; 167(4): 627-38, 2004 Nov 22.
Article in English | MEDLINE | ID: mdl-15545322

ABSTRACT

The DNA repair proteins poly(ADP-ribose) polymerase-1 (PARP-1), Ku86, and catalytic subunit of DNA-PK (DNA-PKcs) have been involved in telomere metabolism. To genetically dissect the impact of these activities on telomere function, as well as organismal cancer and aging, we have generated mice doubly deficient for both telomerase and any of the mentioned DNA repair proteins, PARP-1, Ku86, or DNA-PKcs. First, we show that abrogation of PARP-1 in the absence of telomerase does not affect the rate of telomere shortening, telomere capping, or organismal viability compared with single telomerase-deficient controls. Thus, PARP-1 does not have a major role in telomere metabolism, not even in the context of telomerase deficiency. In contrast, mice doubly deficient for telomerase and either Ku86 or DNA-PKcs manifest accelerated loss of organismal viability compared with single telomerase-deficient mice. Interestingly, this loss of organismal viability correlates with proliferative defects and age-related pathologies, but not with increased incidence of cancer. These results support the notion that absence of telomerase and short telomeres in combination with DNA repair deficiencies accelerate the aging process without impacting on tumorigenesis.


Subject(s)
Aging, Premature/genetics , Antigens, Nuclear/genetics , Cell Transformation, Neoplastic/genetics , DNA Repair/genetics , DNA-Binding Proteins/genetics , Poly(ADP-ribose) Polymerases/genetics , Protein Serine-Threonine Kinases/genetics , Telomerase/physiology , Aging, Premature/metabolism , Aging, Premature/pathology , Animals , Cell Division/genetics , Cell Transformation, Neoplastic/metabolism , Chromosomal Instability/genetics , DNA-Activated Protein Kinase , DNA-Binding Proteins/deficiency , Female , Ku Autoantigen , Longevity/genetics , Male , Mice , Mice, Knockout , Neoplasms/genetics , Neoplasms/metabolism , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/deficiency , Protein Serine-Threonine Kinases/deficiency , Telomerase/deficiency , Telomerase/genetics , Telomere/genetics
20.
iScience ; 19: 572-585, 2019 Sep 27.
Article in English | MEDLINE | ID: mdl-31446222

ABSTRACT

Telomeres are considered potential anti-cancer targets. Most studies have focused on telomerase inhibition, but this strategy has largely failed in clinical trials. Direct disruption of the shelterin complex through TRF1 inhibition can block tumorigenesis in cancer mouse models by a mechanism that involves DNA damage induction and reduction of proliferation and stemness. Any anti-cancer target, however, must fulfill the requisite of not showing deleterious effects in healthy tissues. Here, we show that Trf1 genetic deletion in wild-type and cancer-prone p53- and Ink4Arf-deficient mice does not affect organismal viability and only induces mild phenotypes like decreased body weight and hair graying or hair loss, the skin being the most affected tissue. Importantly, we found that Trf1 is essential for tumorigenesis in p53- and Ink4Arf-deficient mice, as we did not find a single tumor originating from Trf1-deleted cells. These findings indicate a therapeutic window for targeting Trf1 in cancer treatment.

SELECTION OF CITATIONS
SEARCH DETAIL